GLP-1 drugs (including Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Trulicity, Saxenda, and Victoza) are under intense real-world scrutiny as use expands. Regulatory updates can include labeling changes, safety communications, and pharmacovigilance signal reviews—all of which can influence patient awareness, prescribing behavior, and litigation.
Important Regulatory News (April 2026): As of April 1, 2026, the FDA has greenlighted Eli Lilly’s orforglipron (Foundayo). Foundayo is a once-a-day oral GLP-1 pill for weight loss. The FDA approved Foundayo (orforglipron) for obesity, making it the second pill option after Rybelsus and the first for weight loss alone. It is notable that Foundayo has no strict food or water ingestion requirements.
Medicare is about to initiate a “BRIDGE” program in July of 2026. This program will permit limited access to weight loss drugs prior to expected full Medicare coverage in 2027.
Compounding crackdown: The FDA officially declared that GLP-1 for important GLP-1 medications (tirzepatide and semaglutide) are over and done with. As a result, GLP-1 compounders must cease and desist marketing “essentially copies” of GLP-1 branded prescription meds. The FDA warns these ne’er-do-well compounding companies that continuing production could result in enforcement consequences. The FDA is laying down the hammer on compounded GLP-1s. The FDA has declared that any prior shortages of GLP-1 branded drugs such as tirzepatide are finished (resolved).
Scrutiny of Telehealth: The FDA has delivered numerous warnings to telehealth corporations for misleading advertisements and distributing unapproved compounded GLP-1 meds.
Salt Forms: The FDA is also cracking down on salt forms of semaglutide often utilized while compounding. The FDA cites safety and efficacy worries.
This page explains what counts as a regulatory update, where to find the most reliable sources, and which GLP-1 safety topics regulators have highlighted.
Ozempic FDA approval:
Below you will find a comprehensive explanation of Ozempic FDA approval history
- On December 5, 2016, Novo Nordisk approval of Ozempic as weekly injectable Semaglutide to treat type 2 diabetes.
- On January 16, 2020, the FDA approved Ozempic for treatment of cardiovascular disease.
- On March 28, 2022, the FDA approved Ozempic for a larger dose.
Ozempic label updates 2017-2026:
- On December 5, 2017 the FDA approved Ozempic. The Ozempic warning label warned patients about side effects such as: nausea, thyroid c-cell tumors, constipation, risks of pancreatitis, diabetic retinopathy complications, and hypoglycemia when used with insulin and potential kidney issues caused by dehydration. The FDA mandated a box warning related to the link between Semaglutide and the risk of thyroid c-cell tumors, which specifically includes medullary thyroid carcinoma (MTC).
- April 12, 2021: The FDA warned about the risk of hypoglycemia and severe allergic reactions, like anaphylaxis. Warned of adverse reactions when Ozempic is combined with insulin.
- March 28, 2022: (Gallbladder disease) The Ozempic label was modified to add acute gallbladder disease (cholelithiasis and cholecystitis).
- October 6, 2022: (Birth Defects and Miscarriages) The Ozempic label was altered by the Food and drug administration concerning birth defects and miscarriages.
- September 22, 2023: (Gastrointestinal Disorders: Ileus) This update involves the risk of severe hypoglycemia and ileus as an adverse reaction.
- November 1, 2024: (Pulmonary Aspiration) The Ozempic label was changed to add a warning related to pulmonary aspiration during general anesthesia or deep sedation.
- October 2025: FDA warnings: “Use of OZEMPIC has been associated with gastrointestinal adverse reactions, sometimes severe. In OZEMPIC clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving OZEMPIC (0.5 mg 0.4%, 1 mg 0.8%) than placebo (0%). Severe gastrointestinal adverse reactions have also been reported post marketing with GLP-1 receptor agonists. OZEMPIC is not recommended in patients with severe gastroparesis” In October 2025: The FDA also added and amended the following adverse reaction complications (changes underlined) “Gastrointestinal: ileus, intestinal obstruction, severe constipation including fecal impaction, Renal: acute kidney injury…. headache.
What Counts as a “Regulatory Update” for GLP-1 Drugs?
Regulatory updates generally fall into these categories:
- Prescribing Information (label) updates (warnings, contraindications, adverse reactions, postmarketing experience)
- Safety communications from regulators (e.g., FDA pages for patients/providers)
- Pharmacovigilance “signals” reviewed by agencies (e.g., EMA PRAC signal recommendations)
- Actions involving unapproved or illegal products (e.g., counterfeit/“research-only” semaglutide or tirzepatide)
The Most Important U.S. FDA Sources
A) Official FDA labels (Prescribing Information)
For many safety questions, the “source of truth” is the most current FDA label PDF. Example: current Wegovy labeling is available via FDA’s drug label system. (FDA Access Data)
B) FDA postmarket safety pages
The FDA also posts safety updates outside the label—especially around product quality and illegal sales. For example, FDA has warned consumers about unapproved GLP-1 products marketed as “for research purposes” and urged people not to purchase them due to unknown quality and potential harm. (U.S. Food and Drug Administration)
Key EU/EMA Sources to Monitor
A) EMA product information (SmPC / EPAR)
EMA product information may emphasize risks such as delayed gastric emptying and dehydration-related kidney risk language for GLP-1 receptor agonists. (European Medicines Agency (EMA))
B) EMA PRAC signal recommendations
EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) publishes periodic documents listing signal recommendations from PRAC meetings (a key “watch list” for emerging issues). (European Medicines Agency (EMA))
Examples of Safety Topics That Have Driven Public Attention
A) Intestinal blockage / ileus discussions
Public reporting has noted FDA labeling attention around ileus (blocked intestines) for Ozempic in prior years. (Healthline)
B) Delayed gastric emptying and anesthesia/sedation considerations
Regulatory product info and professional materials may highlight delayed gastric emptying and procedural considerations (e.g., residual gastric contents). (European Medicines Agency (EMA))
C) Dehydration and renal function deterioration
EU product information for semaglutide products includes caution that GI adverse reactions may cause dehydration, which in rare cases can lead to deterioration of renal function. (European Medicines Agency (EMA))
Why Regulatory Updates Matter for Lawsuits
Regulatory events can matter in litigation because they may relate to:
- failure-to-warn allegations (what risks were communicated, when, and how clearly)
- foreseeability (whether emerging patterns were recognized)
- patient decision-making (what consumers reasonably understood at the time)
That said, a regulatory update is not required for a valid claim—most case strength still comes from your diagnosis, treatment, and records.
➡️ Evidence guide: Medical Records
➡️ What lawyers look for: What lawyers look for
If You Believe a Regulatory Topic Matches Your Injury
If you experienced hospitalization, surgery, organ injury, or long-term impairment after acknowledges or newly discussed risks, you can start a review with minimal info:
➡️ Start here: File a Claim
➡️ Eligibility criteria: Criteria